Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18


Salvage sacrococcygeal resection for yolk sac tumors after chemotherapy: report of 2 cases.

Ravindra VM, Ruggieri L, Vasudevan SA, Hicks MJ, Muscal JA, Quintanilla NM, Schady DA, Aldave G.

J Neurosurg Pediatr. 2019 Oct 4:1-8. doi: 10.3171/2019.7.PEDS19321. [Epub ahead of print]


Mentors' perspectives on the successes and challenges of mentoring in the COG Young Investigator mentorship program: A report from the Children's Oncology Group.

Esbenshade AJ, Kahalley LS, Baertschiger R, Dasgupta R, Goldsmith KC, Nathan PC, Harker-Murray P, Kitko CL, Kolb EA, Murphy ES, Muscal JA, Pierson CR, Reed D, Schore R, Unguru Y, Venkatramani R, Wistinghausen B, Dhall G.

Pediatr Blood Cancer. 2019 Oct;66(10):e27920. doi: 10.1002/pbc.27920. Epub 2019 Jul 16.


Concurrent Inhibition of Neurosphere and Monolayer Cells of Pediatric Glioblastoma by Aurora A Inhibitor MLN8237 Predicted Survival Extension in PDOX Models.

Kogiso M, Qi L, Braun FK, Injac SG, Zhang L, Du Y, Zhang H, Lin FY, Zhao S, Lindsay H, Su JM, Baxter PA, Adesina AM, Liao D, Qian MG, Berg S, Muscal JA, Li XN.

Clin Cancer Res. 2018 May 1;24(9):2159-2170. doi: 10.1158/1078-0432.CCR-17-2256. Epub 2018 Feb 20.


Small molecule inhibitor regorafenib inhibits RET signaling in neuroblastoma cells and effectively suppresses tumor growth in vivo.

Chen Z, Zhao Y, Yu Y, Pang JC, Woodfield SE, Tao L, Guan S, Zhang H, Bieerkehazhi S, Shi Y, Patel R, Vasudevan SA, Yi JS, Muscal JA, Xu GT, Yang J.

Oncotarget. 2017 Oct 24;8(61):104090-104103. doi: 10.18632/oncotarget.22011. eCollection 2017 Nov 28.


Long-term evidence that a pediatric oncology mentorship program for young investigators is feasible and beneficial in the cooperative group setting: A report from the Children's Oncology Group.

Esbenshade AJ, Pierson CR, Thompson AL, Reed D, Gupta A, Levy A, Kahalley LS, Harker-Murray P, Schore R, Muscal JA, Embry L, Maloney K, Horton T, Zweidler-Mckay P, Dhall G.

Pediatr Blood Cancer. 2018 Mar;65(3). doi: 10.1002/pbc.26878. Epub 2017 Nov 28.


Borderline Ovarian Tumor in the Pediatric and Adolescent Population: A Case Series and Literature Review.

Childress KJ, Patil NM, Muscal JA, Dietrich JE, Venkatramani R.

J Pediatr Adolesc Gynecol. 2018 Feb;31(1):48-54. doi: 10.1016/j.jpag.2017.09.001. Epub 2017 Sep 9. Review.


The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.

Lu J, Guan S, Zhao Y, Yu Y, Woodfield SE, Zhang H, Yang KL, Bieerkehazhi S, Qi L, Li X, Gu J, Xu X, Jin J, Muscal JA, Yang T, Xu GT, Yang J.

Cancer Lett. 2017 Aug 1;400:61-68. doi: 10.1016/j.canlet.2017.04.022. Epub 2017 Apr 26.


Novel Src/Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src/Abl signaling.

Bieerkehazhi S, Chen Z, Zhao Y, Yu Y, Zhang H, Vasudevan SA, Woodfield SE, Tao L, Yi JS, Muscal JA, Pang JC, Guan S, Zhang H, Nuchtern JG, Li H, Li H, Yang J.

Oncotarget. 2017 Jan 3;8(1):1469-1480. doi: 10.18632/oncotarget.13643.


Childhood and adolescent tracheobronchial mucoepidermoid carcinoma (MEC): a case-series and review of the literature.

Jaramillo S, Rojas Y, Slater BJ, Baker ML, Hicks MJ, Muscal JA, Vece TJ, Wesson DE, Nuchtern JG.

Pediatr Surg Int. 2016 Apr;32(4):417-24. doi: 10.1007/s00383-015-3849-y. Epub 2016 Jan 20. Review.


Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis.

Wang Y, Wang L, Guan S, Cao W, Wang H, Chen Z, Zhao Y, Yu Y, Zhang H, Pang JC, Huang SL, Akiyama Y, Yang Y, Sun W, Xu X, Shi Y, Zhang H, Kim ES, Muscal JA, Lu F, Yang J.

Sci Rep. 2016 Jan 20;6:19423. doi: 10.1038/srep19423.


Mucoepidermoid Carcinoma in Children: A Single Institutional Experience.

Techavichit P, Hicks MJ, López-Terrada DH, Quintanilla NM, Guillerman RP, Sarabia SF, Sayeed H, Nuchtern JG, Paulino AC, Muscal JA, Okcu MF, Chintagumpala M.

Pediatr Blood Cancer. 2016 Jan;63(1):27-31. doi: 10.1002/pbc.25681. Epub 2015 Jul 29.


Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors.

Norris RE, Shusterman S, Gore L, Muscal JA, Macy ME, Fox E, Berkowitz N, Buchbinder A, Bagatell R.

Pediatr Blood Cancer. 2014 Oct;61(10):1792-7. doi: 10.1002/pbc.25105. Epub 2014 Jun 24.


A phase I trial of imetelstat in children with refractory or recurrent solid tumors: a Children's Oncology Group Phase I Consortium Study (ADVL1112).

Thompson PA, Drissi R, Muscal JA, Panditharatna E, Fouladi M, Ingle AM, Ahern CH, Reid JM, Lin T, Weigel BJ, Blaney SM.

Clin Cancer Res. 2013 Dec 1;19(23):6578-84. doi: 10.1158/1078-0432.CCR-13-1117. Epub 2013 Oct 4.


A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916).

Muscal JA, Thompson PA, Horton TM, Ingle AM, Ahern CH, McGovern RM, Reid JM, Ames MM, Espinoza-Delgado I, Weigel BJ, Blaney SM.

Pediatr Blood Cancer. 2013 Mar;60(3):390-5. doi: 10.1002/pbc.24271. Epub 2012 Aug 9.


Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines.

Muscal JA, Scorsone KA, Zhang L, Ecsedy JA, Berg SL.

Invest New Drugs. 2013 Feb;31(1):39-45. doi: 10.1007/s10637-012-9831-9. Epub 2012 Jun 6.


Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates.

Muscal JA, Sun Y, Nuchtern JG, Dauser RC, McGuffey LH, Gibson BW, Berg SL.

Cancer Chemother Pharmacol. 2012 Apr;69(4):943-7. doi: 10.1007/s00280-011-1781-y. Epub 2011 Nov 23.


Plasma and cerebrospinal fluid pharmacokinetics of ABT-888 after oral administration in non-human primates.

Muscal JA, Thompson PA, Giranda VL, Dayton BD, Bauch J, Horton T, McGuffey L, Nuchtern JG, Dauser RC, Gibson BW, Blaney SM, Su JM.

Cancer Chemother Pharmacol. 2010 Feb;65(3):419-25. doi: 10.1007/s00280-009-1044-3. Epub 2009 Jun 13.


Changes mimicking new leptomeningeal disease after intensity-modulated radiotherapy for medulloblastoma.

Muscal JA, Jones JY, Paulino AC, Bertuch AA, Su J, Woo SY, Mahoney DH Jr, Chintagumpala M.

Int J Radiat Oncol Biol Phys. 2009 Jan 1;73(1):214-21. doi: 10.1016/j.ijrobp.2008.03.056. Epub 2008 May 15.

Supplemental Content

Loading ...
Support Center